The US Food and Drug Administration showed off its willingness to allow for regulatory flexibility in in certain clinical development programs with its approval of the Global Alliance for TB Drug Development's pretomanid regimen, but the agency also inserted restrictions in the labeling to help ensure its use remains limited.
Pretomanid got the green light on 14 August with a limited population antibacterial drug (LPAD) designation – only the second...






